Immunogen Insights: Return On Capital Employed

Immunogen IMGN reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52 million, and sales totaled $85.80 million in Q4.

What Is ROCE?

Changes in earnings and sales indicate shifts in Immunogen's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Immunogen posted an ROCE of -0.31%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Immunogen is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In Immunogen's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q1 Earnings Insight

Immunogen reported Q1 earnings per share at $-0.17/share, which beat analyst predictions of $-0.19/share.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsBZI-ROCE
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!